- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Anti-Aging
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
The Toxin Head-to-Head Challenge
For answers, Dermatology Times and Cosmetic Surgery Times developed an online survey for readers. The activity presented images from 6 patients who were photographed on the day of their injection and 30 days after treatment with either Xeomin® (incobotulinumtoxinA, Merz Pharmaceuticals) or Botox® (onabotulinumtoxinA, Allergan).
Have you ever asked, “How do treatment outcomes compare between botulinum toxins”?
For answers, Dermatology Times and Cosmetic Surgery Times developed an online survey for readers. The activity presented images from 6 patients who were photographed on the day of their injection and 30 days after treatment with either Xeomin® (incobotulinumtoxinA, Merz Pharmaceuticals) or Botox® (onabotulinumtoxinA, Allergan).
Participants were asked to determine, if they could, which injectable toxin each patient received - and results showed that physicians were unable to accurately identify the toxin used.
This supplement details the pulse poll, the head-to-head trial, and the Xeomin pivotal trials.
